[Skip to Navigation]
Views 1,111
Citations 0
Comment & Response
October 3, 2022

Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease—Estimating the True Value

Author Affiliations
  • 1Program on Regulation, Therapeutics, and Law, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 2Harvard Medical School, Boston, Massachusetts
JAMA Neurol. 2022;79(11):1204. doi:10.1001/jamaneurol.2022.3101

To the Editor Alzheimer disease (AD) can be clinically devastating and costly, given its potential to profoundly impair quality of life and activities of daily living. Ross et al1 sought to evaluate cost-effectiveness of controversial novel antiamyloid monoclonal antibodies aducanumab and donanemab, which aim to slow AD progression. The US Food and Drug Administration (FDA), despite dissent of its expert advisory committee, approved aducanumab under the accelerated approval pathway in 2021, based on the surrogate end point of reduction in cerebral amyloid-β plaque, and is currently considering donanemab for accelerated approval on similar grounds.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words